Leap Therapeutics Inc expected to post a loss of 90 cents a share - Earnings Preview

Cypherpunk Technologies

08/08/2023 16:17

* Leap Therapeutics Inc  LPTX.OQ   LPTX.O  is expected
to show no
change in quarterly revenue when it reports  results on August
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Leap Therapeutics
Inc is
for a loss of 90 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Leap
Therapeutics
Inc is $25​, above​ its last closing price of $2.47. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.00       -0.98      -3.20     Missed  -226.5
 Dec. 31 2023              -1.10      -1.00     Beat    9.1
 Sep. 30 2022  -1.25       -1.20      -1.30     Missed  -8.3​
 Jun. 30 2022  -0.95       -0.96      -1.50     Missed  -56.2
 ​​Mar.        -1.00       -1.00      -0.90     Beat    10
 31 2022                                                
 Dec. 31 2021  -1.18       -1.10      -1.00     Beat    9.1​
 Sep. 30 2021  -0.95       -1.12      -1.40     Missed  -25
 Jun. 30 2021  -1.25       -1.25      -1.20     Beat    4
 This summary was machine generated August 8 at 15:17 GMT.  All
figures in US dollars  unless otherwise stated